In the past few years, semaglutide has become one of the most talked-about medical weight loss treatments in decades. Originally developed for type 2 diabetes management, it has since received FDA approval specifically for chronic weight management — and the clinical results have been remarkable enough to change how clinicians think about obesity treatment. If you are curious about whether it might be appropriate for you, this guide covers the science, the realities, and what to expect from the process.
What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic peptide that mimics the action of GLP-1, a hormone your gut naturally releases after you eat. GLP-1 plays several important roles:
- It signals the pancreas to release insulin in response to elevated blood glucose
- It suppresses glucagon (which would otherwise raise blood sugar)
- It slows gastric emptying, meaning food moves more slowly from your stomach to your small intestine
- It acts on the brain’s appetite regulation centers to reduce hunger and increase feelings of fullness
The result is a medication that works through multiple pathways simultaneously: you feel less hungry, feel full sooner, have fewer food cravings, and your blood sugar remains more stable. For many people, the effect on appetite is described as a significant quieting of what researchers sometimes call “food noise” — the constant mental preoccupation with food that many people with obesity experience.
Semaglutide is marketed under two brand names: Ozempic (the 0.5–2 mg once-weekly injection approved for type 2 diabetes) and Wegovy (the 2.4 mg once-weekly injection approved for chronic weight management). The active ingredient is identical; the approved dose and indication differ.
FDA Approval for Weight Loss
The FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in June 2021, based on a phase 3 clinical trial program called STEP (Semaglutide Treatment Effect in People with Obesity). This was a significant moment: it marked the first approval of a new weight loss mechanism in nearly a decade, and the efficacy data was substantially stronger than prior weight loss medications.
The FDA indication is for adults with:
- A body mass index (BMI) of 30 or greater (obesity), OR
- A BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol
It is approved as an adjunct to a reduced-calorie diet and increased physical activity — meaning it is not intended to replace lifestyle changes, but to work alongside them.
What Results Can You Realistically Expect?
The STEP 1 trial — the pivotal study for Wegovy’s approval — enrolled adults with obesity (no diabetes) who received semaglutide 2.4 mg or placebo for 68 weeks, alongside lifestyle intervention counseling. The results:
- Average weight loss in the semaglutide group: 14.9% of body weight (approximately 33 lbs on average)
- 69% of participants achieved at least 10% weight loss
- 50% of participants achieved at least 15% weight loss
- 30% of participants achieved at least 20% weight loss
These are averages — individual results vary considerably. Factors that influence response include starting weight, baseline metabolic health, adherence to dietary changes, activity level, and how well individual patients tolerate the medication. Some people are robust responders who lose 20%+ of body weight; others see more modest results.
A critical finding from follow-up research: when semaglutide is discontinued, a significant portion of the weight lost tends to return over the following year unless lifestyle changes have been firmly established. This underscores that semaglutide is a treatment for a chronic condition, not a temporary fix. Most providers approach it as a long-term or indefinite therapy, similar to how blood pressure medication is prescribed for hypertension.
How Treatment Works: The Dose Escalation Schedule
Semaglutide is not started at the full therapeutic dose. A gradual escalation protocol is used to allow the body to adjust and to minimize gastrointestinal side effects. The standard Wegovy escalation schedule is:
- Weeks 1–4: 0.25 mg once weekly (initiation dose)
- Weeks 5–8: 0.5 mg once weekly
- Weeks 9–12: 1.0 mg once weekly
- Weeks 13–16: 1.7 mg once weekly
- Week 17+: 2.4 mg once weekly (maintenance dose)
If side effects are significant at any stage, your provider may recommend staying at the current dose longer before escalating. Not everyone reaches the full 2.4 mg maintenance dose — some patients find a lower dose sufficient or better tolerated.
Semaglutide for weight loss is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Auto-injector pens make self-administration straightforward, and most patients become comfortable with the process within a few weeks.
Side Effects: What to Know Before You Start
Semaglutide has a well-characterized side effect profile. The most common effects are gastrointestinal and are most pronounced during dose escalation:
- Nausea: The most common side effect, reported in approximately 44% of participants in clinical trials. It is typically worst in the first few weeks after a dose increase and tends to improve as the body adjusts.
- Vomiting: Reported in approximately 24% of trial participants. Usually manageable but can be significant for some.
- Diarrhea: Reported in approximately 30% of participants.
- Constipation: Also common, as gastric emptying slows significantly.
- Fatigue: Some patients report fatigue, particularly early in treatment.
- Reduced appetite: While this is the intended mechanism, it can be pronounced enough that some patients struggle to eat adequate nutrition. Protein intake in particular requires attention.
Less common but more serious considerations include:
- Pancreatitis: GLP-1 agonists carry a warning regarding pancreatitis risk. Report any persistent, severe abdominal pain to your provider immediately.
- Gallbladder disease: Rapid weight loss of any kind can increase gallstone risk. Semaglutide may further elevate this risk.
- Heart rate: Semaglutide may increase resting heart rate slightly. Cardiovascular monitoring is recommended.
- Thyroid C-cell tumors: Semaglutide carries an FDA black box warning regarding thyroid C-cell tumors based on animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Semaglutide is also contraindicated during pregnancy and should be discontinued before becoming pregnant. It is not approved for use in children under 12.
What About Compounded Semaglutide?
Due to high demand and brand-name drug shortages in 2023 and 2024, compounding pharmacies began producing semaglutide at much lower prices. The FDA had placed semaglutide on its drug shortage list, permitting this practice. However, as of early 2025, the FDA removed semaglutide from the shortage list, signaling that compounding pharmacies may no longer legally compound copies of the branded product in most circumstances.
The landscape continues to evolve. If a provider offers compounded semaglutide, ask questions about the pharmacy’s credentials, testing practices, and the current regulatory status. The risk with unregulated compounded peptides is variable product quality and uncertain dosing accuracy.
How Much Does Semaglutide Cost?
Cost is one of the most significant practical barriers for many patients. Here is the general landscape:
- Brand-name Wegovy: List price approximately ,300–,400 per month. With commercial insurance coverage (where available), copays may be significantly lower. Many insurance plans still exclude obesity medications, though coverage has been expanding.
- Novo Nordisk savings programs: The manufacturer offers savings cards that can reduce out-of-pocket costs for commercially insured patients who qualify.
- Medicare/Medicaid: Medicare Part D began covering Wegovy for cardiovascular risk reduction in 2024, following the SELECT trial showing significant cardiovascular benefits. Coverage for weight loss alone under Medicare remains limited.
- Medical weight loss clinic fees: Beyond medication cost, clinics typically charge for initial consultation (–), lab work, and monthly monitoring visits.
The overall cost picture means that for many patients, compounded semaglutide — when legally available — or telehealth programs with access to manufacturer savings cards may be the most accessible path. Your provider can help navigate what is available in your situation.
The Muscle Loss Question
One concern that has received increasing attention is the potential for significant muscle mass loss alongside fat loss on semaglutide. When weight is lost rapidly and caloric intake drops substantially, the body can draw on muscle protein for energy. Research suggests that a meaningful portion of weight lost on GLP-1 agonists may come from lean mass rather than fat alone.
Strategies that may help preserve muscle during treatment include:
- Maintaining adequate protein intake (many providers recommend 1.2–1.6 grams of protein per kilogram of body weight)
- Consistent resistance training
- Avoiding excessively aggressive caloric restriction beyond what the medication naturally induces
Discuss muscle preservation strategies with your provider before starting treatment.
Finding a Weight Loss Provider
Semaglutide requires a prescription and ongoing medical supervision. A quality weight loss clinic will:
- Conduct a full health evaluation including labs before prescribing
- Screen appropriately for contraindications (thyroid history, pancreatitis history, etc.)
- Provide dietary and lifestyle guidance alongside the medication
- Monitor your progress, weight, and relevant health markers regularly
- Have a clear plan for what happens if you experience significant side effects or if the medication is discontinued
Browse BlushLocal’s weight loss clinic directory to find reviewed providers offering medical weight loss programs near you. You can also explore the broader peptide and hormone wellness directory to find clinics that combine weight management with hormonal optimization for a more comprehensive approach.
The Bottom Line
Semaglutide represents a genuine advance in medical weight management. The clinical evidence for meaningful weight loss in appropriate candidates is robust, and for many people who have struggled with weight for years despite lifestyle efforts, it can be genuinely life-changing. But it is not a magic solution — it works best as part of a comprehensive approach that includes nutrition, movement, and behavioral support, and the question of long-term use and cost requires honest planning.
If you think you might be a candidate, start with a consultation at a qualified weight loss clinic. Bring your medical history, any existing labs, and honest questions about cost and expectations. The right provider will give you a clear-eyed assessment of whether semaglutide is appropriate for your situation — and what a realistic treatment plan looks like for you.
